Relvinca Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Vinorelbine

Indications/Uses

NSCLC; advanced breast cancer in adults.

Dosage/Direction for Use

Adult 1st 3 administrations: 60 mg/m² once wkly as single agent. Subsequent administrations: Increase dose to 80 mg/m² once wkly after 3rd administration. Patient w/ neutrophils >1,000/mm³; or >500 & <1,000/mm³ (1 episode) Recommended dose starting w/ 4th administration: 80 mg/m² once wkly, neutrophils >500 & <1,000/mm³ (2 episodes); or <500/mm³ Recommended dose starting w/ 4th administration: 60 mg/m² once wkly. Mild hepatic impairment 60 mg/m² once wkly. Moderate hepatic impairment 50 mg/m² once wkly.

Administration

Should be taken with food: Swallow whole w/ water; do not chew, suck or dissolve the softcap.

Contraindications

Hypersensitivity to vinorelbine or other vinca alkaloids. Disease significantly affecting absorption. Previous significant surgical resection of stomach or small bowel. Neutrophil count <1,500/mm³ or current/recent severe infection (w/in 2 wk). Platelet count <100,000/mm³. Patients requiring long-term O₂ therapy. Combination w/ yellow fever vaccine. Lactation.

MIMS Class

Cytotoxic Chemotherapy

ATC Classification

L01CA04 - vinorelbine ; Belongs to the class of plant alkaloids and other natural products, vinca alkaloids and analogues. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Relvinca softcap 20 mg

Packing/Price

1's

Form

Relvinca softcap 30 mg

Packing/Price

1's

Relvinca

vinorelbine

Manufacturer:

Lotus Pharmaceutical